Last reviewed · How we verify
Hemp-based CBD
At a glance
| Generic name | Hemp-based CBD |
|---|---|
| Also known as | Ananda Hemp CBD Spectrum Gelcaps |
| Sponsor | Main Line Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic Evaluation of a Natural CBD Extract (NA)
- Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy (EARLY_PHASE1)
- CBD for Knee Osteoarthritis (PHASE1, PHASE2)
- Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder (PHASE2)
- Cannabidiol for Reducing Cigarette Use (PHASE2)
- Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder (PHASE2)
- Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease (PHASE3)
- The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemp-based CBD CI brief — competitive landscape report
- Hemp-based CBD updates RSS · CI watch RSS
- Main Line Health portfolio CI